| [1] |
ZHONG Wei, SHI Shuxia, QIN Qinyue, YU Guo.
Measurement tools and rationality evaluation of clinical research coordinator's work ability and workload
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 937-947.
|
| [2] |
HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie.
Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696.
|
| [3] |
QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei.
Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
|
| [4] |
LI Yanyang, WANG Yunjiao, LV Shichao.
Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
|
| [5] |
LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao.
Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
|
| [6] |
QI Xiaofeng, LUO Yali, XIAO Mengyong, ZHOU Shiqin, ZHOU Wen, AN Fangyu, WEI Benjun, LIU Yongqi.
Research status of dialectical prevention and treatment of acute lung injury based on the theory of "Wei qi and Ying Xue"
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 429-437.
|
| [7] |
WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun.
Clinical research progress of palbociclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
|
| [8] |
DAI Jiahui, SUN Sijia, XIE Xuefeng.
Quality management and indicator system for clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
|
| [9] |
CHEN Jianfang, LOU Donghua.
Design of case report form for oncology clinical trials based on CDASH
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
|
| [10] |
LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin.
Ethical analysis and countermeasures of artificial intelligence application in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
|
| [11] |
CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing.
Research progress on antipyretic effect of Chinese medicine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.
|
| [12] |
ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li.
Clinical trials of inhalation in pediatric population in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
|
| [13] |
SHI Gexin, CHONG Rui, HE Kun, WU Haitang, ZHOU Yu, DUN Zhongjun, WEN Qing, ZHANG Jiguo, ZHANG Rong.
A fully replicated crossover bioequivalence study of mycophenolate mofetil capsules in Chinese healthy male subjects under fasting and fed conditions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1255-1263.
|
| [14] |
WANG Wenjuan, QI Mingrui, TIAN Limin.
Research progress on Nrf2 in diabetic cardiomyopathy and intervention of traditional Chinese medicine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1163-1170.
|
| [15] |
ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang.
Research progress of PARP inhibitors in pancreatic cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
|
